1,3-二氢-1-丙基-(9ci)-2H-苯并咪唑-2-酮 | 77557-01-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1,3-二氢-1-丙基-(9ci)-2H-苯并咪唑-2-酮
• 英文名称: 1-propyl-1,3-dihydro-2H-benzo[d]imidazol-2-one
• 英文别名: 1-propyl-1,3-dihydro-2H-benzimidazol-2-one；3-propyl-1H-benzimidazol-2-one
• CAS: 77557-01-8
• 化学式: C₁₀H₁₂N₂O
• mdl: MFCD02707887
• 分子量: 176.218
• InChiKey: YNFLIDHXMNKSQR-UHFFFAOYSA-N

物化性质

• 熔点：
  104 °C(Solv: benzene (71-43-2); ligroine (8032-32-4))
• 密度：
  1.128±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

ADMET

代谢

1-丙基-1,3-二氢-2H-苯并咪唑-2-酮是多潘立酮的已知人体代谢物。

1-Propyl-1,3-dihydro-2H-benzimidazol-2-one is a known human metabolite of domperidone.

来源:NORMAN Suspect List Exchange

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Propyl-3H-1,3-benzodiazol-2-one
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Propyl-3H-1,3-benzodiazol-2-one
CAS number: 77557-01-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H12N2O
Molecular weight: 176.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1,3-二氢-1-丙基-(9ci)-2H-苯并咪唑-2-酮 在 甲烷 、 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 47.0h， 生成 N-[2-(4-methylpiperazin-1-yl)ethyl]-2-oxo-3-propylbenzimidazole-1-carboxamide
  参考文献：
  名称：

  对5-HT（4）受体具有选择性亲和力的2,3-二氢-2-羰基-1H-苯并咪唑-1-羧酰胺：一系列新的部分激动剂和拮抗剂衍生物的合成，结构亲和力和结构活性关系。

  摘要：

  合成了一系列带有哌嗪部分的2，3-二氢-2-氧代-1H-苯并咪唑-1-羧酰胺衍生物。他们的体外5-HT（4），5-HT（3）和D（2）受体亲和力通过放射性配体结合测定法进行了评估。对于选定的化合物，通过使用大鼠食管肌膜粘膜（TMM）的预收缩（卡巴胆碱）制剂对5-HT（4）受体进行功能研究。研究了苯并咪唑环的3-取代基，哌嗪部分的4-取代基和亚烷基间隔基的影响。在苯并咪唑环的3位上具有乙基或环丙基取代基的化合物显示出对5-HT（4）受体的中等至高亲和力（K（i）= 6.7-75.4 nM），对5-HT（3）的选择性）和D（2）受体和中等拮抗活性（pK（b）= 6.19-7.73）。在3-苯并咪唑位置具有异丙基取代基的化合物显示出中等和选择性的5-HT（4）亲和力（K（i）> / = 38.9 nM）和部分激动剂活性（5a，ia = 0.94）参考化合物BIMU 8（ia = 0.70）。仅由

  DOI：

  10.1021/jm981098j
• 作为产物：
  描述：

  2-Propylamino-benzamid 在 氢氧化钾 、 碘苯二乙酸 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以72%的产率得到1,3-二氢-1-丙基-(9ci)-2H-苯并咪唑-2-酮
  参考文献：
  名称：

  邻氨基苯甲酰胺、水杨酰胺和一些β-取代酰胺的高价碘氧化重排：2-苯并咪唑酮、2-苯并恶唑酮和相关化合物的新型便捷合成

  摘要：

  在甲醇氢氧化钾中用碘苯二乙酸酯氧化邻氨基苯甲酰胺、水杨酰胺和一些β-取代的酰胺，分别导致2-苯并咪唑酮、2-苯并恶唑酮和相关化合物的新且方便的合成。该反应可能通过最初的霍夫曼型重排发生，然后是中间体异氰酸酯的分子内环化。

  DOI：

  10.1055/s-2001-12346

文献信息

• Photocatalytic Intramolecular C–H Amination Using <i>N</i>-Oxyureas as Nitrene Precursors
  作者：Ryan A. Ivanovich、Dilan E. Polat、André M. Beauchemin

  DOI：10.1021/acs.orglett.0c02200

  日期：2020.8.21

  Nitrenes are remarkable high-energy chemical species that enable direct C–N bond formation, typically via controlled reactions of metal-stabilized nitrenes. Here, in contrast, the combined use of photocatalysis with careful engineering of the precursor enabled C–H amination forming imidazolidinones and related nitrogen heterocycles from readily accessible hydroxylamine precursors. Preliminary mechanistic

  硝基是非凡的高能化学物质，通常可通过金属稳定的腈的受控反应直接形成C-N键。相比之下，光催化与前体的精心设计相结合，可以使C–H胺化反应从易得的羟胺前体形成咪唑烷酮和相关的氮杂环。初步的机理结果与游离氨基甲酰基三重态氮烯作为反应性中间体的形成是一致的。
• [EN] RESPIRATORY SYNCYTIAL VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS RESPIRATOIRE SYNCYTIAL
  申请人：MEDIVIR AB

  公开号：WO2015065336A1

  公开（公告）日：2015-05-07

  Compounds of Formula (I): wherein R1, R2 and R3 are defined herein, are useful as inhibitors of RSV.

  式(I)的化合物：其中R1、R2和R3如本文所定义，可用作RSV的抑制剂。
• Phenylaminopropanol derivatives and methods of their use
  申请人：Kim Younghee Callain

  公开号：US20050222148A1

  公开（公告）日：2005-10-06

  The present invention is directed to phenylaminopropanol derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及式I的苯胺丙醇衍生物： 或其药学上可接受的盐，含有这些衍生物的组合物，以及它们用于通过单胺再摄取改善的症状的预防和治疗方法，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠道和泌尿系统疾病、慢性疲劳综合征、纤维肌痛综合征、神经系统疾病，以及其中的组合，特别是从包括重性抑郁障碍、血管运动症状、压力性和切勿性尿失禁、纤维肌痛、疼痛、糖尿病性神经病变以及其中的组合的一组中选择的那些症状。
• Substituted propylamine derivatives and methods of their use
  申请人：McComas Cameron Casey

  公开号：US20070072928A1

  公开（公告）日：2007-03-29

  The present invention is directed to substituted propylamine derivatives of formula I: or a pharmaceutically acceptable salt thereof, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, and combinations thereof, particularly those conditions selected from the group consisting of major depressive disorder, vasomotor symptoms, stress and urge urinary incontinence, fibromyalgia, pain, diabetic neuropathy, and combinations thereof.

  本发明涉及具有以下结构的取代丙基胺衍生物：或其药学上可接受的盐，含有这些衍生物的组合物，以及它们用于预防和治疗由单胺再摄取改善的病况的方法，包括但不限于血管运动症状（VMS）、性功能障碍、胃肠和泌尿系统紊乱、慢性疲劳综合征、纤维肌痛综合征、神经系统紊乱，以及由此组合而成的病况，特别是从包括重度抑郁症、血管运动症状、压力和急迫性尿失禁、纤维肌痛综合征、疼痛、糖尿病神经病变等病况中选择的那些病况。
• Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors
  作者：Puwen Zhang、Eugene A. Terefenko、Casey C. McComas、Paige E. Mahaney、An Vu、Eugene Trybulski、Elizabeth Koury、Grace Johnston、Jenifer Bray、Darlene Deecher

  DOI：10.1016/j.bmcl.2008.10.026

  日期：2008.12

  A series of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors was discovered. Several compounds such as 15 and 20 showed good hNET potency. Compounds 15 and 20 also displayed excellent selectivity at hNET that appeared superior to those of reboxetine and atomoxetine (4 and 5).

  发现了一系列新型的1-或3-（3-氨基-1-苯基丙基）-1,3-二氢-2H-苯并咪唑-2-酮作为选择性去甲肾上腺素再摄取抑制剂。几种化合物（例如15和20）显示出良好的hNET效力。化合物15和20在hNET上也表现出优异的选择性，似乎优于瑞波西汀和阿托西汀（4和5）。